Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT04777838 |
| Other study ID # |
ADP2021 |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
Phase 2/Phase 3
|
| First received |
|
| Last updated |
|
| Start date |
March 2021 |
| Est. completion date |
May 2021 |
Study information
| Verified date |
March 2021 |
| Source |
University of Coimbra |
| Contact |
Bruno M Sousa |
| Phone |
+351962607005 |
| Email |
bsousa[@]fmed.uc.pt |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The aim of this study is evaluate the effectiveness of the use of antidepressants in the
treatment of muscle type temporomandibular disorders, with a sample of 60 to 80 participants.
Description:
Temporomandibular Disorders (TMDs) involve alterations of the temporomandibular joint (TMJ),
masticatory muscles, and related structures.
Epidemiologic data indicates that 33% of the general population has at least one symptom of a
temporomandibular disorder (TMD) and 6% to 7% have TMDs severe enough to seek specific
treatment.
The etiology of pain and disability in myofascial pain is understood via a bio- psychosocial
model reflecting a complex interaction between physical, behavioral, social, and
psychological factors. In turn, the treatment of myofascial pain is often multimodal.
Ongoing pain may be associated with co-morbid conditions such as anxiety, depression and
sleeplessness. It is important to recognize and treat emotional distress as well as physical
symptoms. Chronic pain and depression seem to share common neurochemical substrata and
perhaps even similar dysfunctional alterations.
Chronic syndromes such as bruxism and TMD are commonly associated with depression. Research
Investigator reported that 39% of patients with TMD are moderately to severely depressed and
55% have moderate to severe somatization symptoms. A cross-cultural study by List and Dworkin
supported these findings, showing that 45% of Swedish patients and 51% of American patients
who met the diagnostic criteria for TMD also suffered from moderate to severe depression.
If pain assumes a chronic nature, more centrally mediated mechanisms take effect, for which
peripherally acting analgesics have less efficacy. The clinician must recognize the involved
alterations in pain characteristics, such as quality, duration, and intensity, as peripheral
pain becomes more continuous, diffuse, and difficult to localize. In such instances, the
possibility of new targets for treatment emerges.
The prominence of tryciclic antidepressants (TCAs) as a first-line treatment has declined
over time and the introduction of more tolerable medications such as the selective serotonin
reuptake inhibitors (SSRIs) has been done. TCAs are still used today, but they are most
commonly prescribed for patients whose depression does not respond to SSRIs or serotonin and
norepinephrine reuptake inhibitors (SNRIs). TCAs are also used to treat depressed patients
with somatization pain or insomnia, due to their low addictive risk and sedative and
analgesic qualities; however, TCAs are associated with a high suicide risk when taken in
overdose.
For the past several years, tricyclic antidepressants have been used successfully to manage
and control a variety of chronic pain conditions. Research Investigators reported that a
pharmacological protocol for the control of pain associated with chronic temporomandibular
disorders (TMD) based on the use of amitriptyline and found that 25 mg/day of amitriptyline
was sufficient to significantly reduce the pain of chronic TMD without producing side
effects.
Research Investigator showed that 75 mg of amitriptyline provided significantly more pain
relief than 25 or 50mg in patients with chronic pain. However, the patients on higher doses
also had more adverse events such as dry mouth and drowsiness. It should also be kept in mind
that no dose-response relation- ship has been demonstrated for the antidepressant or mood
effects of amitriptyline.
Research Investigator compared the effectiveness of cognitive behavioral therapy (CBT) and
amitriptyline in combination and separately in patients with chronic TMD. They discovered
improvements in all subgroups (CBT alone, amitriptyline alone, CBT plus amitriptyline, and
the placebo group) with an average decrease in pain intensity of 55%. The combination group
of CBT plus amitriptyline, however, was the only group that continued to show improved scores
on the visual analog pain scale at the follow-up 4 weeks after treatment was completed.
The neurotransmitter serotonin regulates a wide range of functions including sleep,
temperature, and mood. Based on that we could suggest that it has a positive impact on
Chronic Pain patients. However, Serotonin also suppresses dopamine release from the
mesocortical tract, which can result in serotonin-induced disinhibition of movement. In other
words, dopamine functions to prevent spontaneous movements, but if serotonin inhibits the
action of dopamine, then spontaneous movements can occur. This is thought to be one of the
most plausible mechanisms involved in the repetitive muscle contractions seen in bruxism.
This mechanism also explains how the SSRIs, which increase concentrations of serotonin, have
the ability to deregulate movement and induce bruxism.
